Skip to main content

Table 3 Changes in number of headache days, and migraine disability scores before and after supplementation with vitamin D or placebo in episodic migraine patients with/without aura

From: The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial

 

Study sub-groups

P value*

Patients with migraine with aura

Patients with migraine without aura

Vitamin D

Placebo

Vitamin D

Placebo

Number of Headache Days per month

 Baseline

10.58 (3.67) a,b

7.75 (3.86)

6.81 (2.43) a

7.67 (3.29) b

0.008

 After the trial

6.00 (3.45)

7.50 (3.32)

4.63 (2.40) a

7.17 (4.11) a

0.029

 Changes

−4.58 (3.76) a,b

−0.25 (3.05) a

−2.09 (2.27)

− 0.10 (2.91) b

0.000

P value#

0.001

0.801

< 0.001

0.868

 

Migraine Related Disability (MIDAS score)

 Baseline

40.00 (26.38)

37.90 (18.53)

24.81 (10.80)

36.53 (22.75)

0.057

 After the trial

23.08 (24.42)

42.90 (25.15) a

17.59 (10.94) a.b

32.46 (16.44) b

0.001

 Changes

−16.92 (15.39) a,b

5.00 (20.18) a

−7.22 (9.25)

−1.46 (12.20) b

0.001

P value#

0.002

0.453

< 0.001

0.547

 
  1. Data are presented as mean (standard deviation)
  2. Alphabets represent significant differences between each variable and two other variables, calculated by Bonferroni test (post-hoc)
  3. *One-way analysis of variance (ANOVA)
  4. # Paired sample t-test